Comparable drug levels and immunogenicity in patients with axial spondyloarthritis treated with adalimumab originator and biosimilar: A retrospective study from two centers of China-Reference-Cited by-同舟云学术

Comparable drug levels and immunogenicity in patients with axial spondyloarthritis treated with adalimumab originator and biosimilar: A retrospective study from two centers of China

Published:2024-05 Issue:5 Volume:27 Page:
ISSN:1756-1841
Container-title:International Journal of Rheumatic Diseases
language:en
Short-container-title:Int J of Rheum Dis

Author:

Fu Zhong‐Chao¹^ORCID,Cheng Xiao‐Gui²,Zhang Guo‐Wen³^ORCID,Shi Ran‐Geng¹,Zhang Li‐Jun³^ORCID,Sun Hai‐Tian⁴,Huang Jin‐Xian⁵^ORCID

Affiliation:

1. Division of Rheumatology, Department of Medicine The Third Affiliated Hospital of Shenzhen University Shenzhen Guangdong China

2. Department of Pharmacy The Third Affiliated Hospital of Shenzhen University Shenzhen Guangdong China

3. Department of Pathological Medicine The University of Hong Kong‐Shenzhen Hospital Shenzhen Guangdong China

4. Special Inspection Project Department Guangzhou Huayin Medical Examination Center Guangzhou Guangdong China

5. Division of Rheumatology, Department of Medicine The University of Hong Kong‐Shenzhen Hospital Shenzhen Guangdong China

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1756-185X.15190

Reference10 articles.

1. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

2. EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases

3. Comparative assessment of pharmacokinetic parameters between HS016, an adalimumab biosimilar, and adalimumab (Humira®) in healthy subjects and ankylosing spondylitis patients: Population pharmacokinetic modeling

4. IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial

5. Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine